Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is commonly
upregulated in cancers such as in non-small-cell lung cancer, metastatic colorectal cancer …

Lineage plasticity, a process whereby cells change their phenotype to take on a different
molecular and/or histologic identity, is a key driver of cancer progression and therapy …

Background Meta-analyses were conducted to characterize patterns of mutation incidence
in non small-cell lung cancer (NSCLC). Design Nine genes with the most complete …

Drug resistance is a major cause for therapeutic failure in non-small cell lung cancer
(NSCLC) leading to tumor recurrence and disease progression. Cell intrinsic mechanisms of …

According to rapid development of chemotherapy in advanced non-small cell lung cancer
(NSCLC), the Japan Lung Cancer Society has been updated its own guideline annually …

Until recently, the division of pulmonary carcinomas into small cell lung cancer (SCLC) and
non-small cell lung cancer (NSCLC) was adequate for therapy selection. Due to the …

Background The therapeutic efficacy of epidermal growth factor receptor tyrosine kinase
inhibitors (EGFR-TKIs) in advanced EGFR-mutant lung squamous cell carcinoma (SCC) …

Background Treatments of non-small-cell lung cancer (NSCLC)—particularly of the
squamous subtype—are limited. In this article, we describe the immunomodulatory …